We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Attorney General is seeking $38 billion over 15 years to cover the state’s opioid-related treatment, public education, and criminal justice costs, along with billions more in unspecified damages. Read More
Chief among Cures 2.0’s offerings is the establishment of a new research-focused agency called the Advanced Research Projects Agency for Health. Read More
The House debated the Build Back Better Act late into the night and was expected to pass the bill, which includes provisions aimed at lowering the price of some prescription drugs. Read More
The U.S. government will pay Pfizer $5.29 billion for 10 million treatment courses of its experimental COVID-19 antiviral, Paxlovid (PF-07321332; ritonavir), to be delivered later this year and into 2022. Read More
A federal judge has cleared Pfizer’s $345 million settlement resolving claims the drugmaker overcharged for its EpiPen epinephrine self-injector for treatment of severe allergic reactions. Read More
The companies said they will supply an unspecified number of doses by mid-December and that the government has an option to purchase additional doses through March 2022. Read More
The FDA launched an agencywide initiative in July — the FDA Inspectional Affairs Council (FIAC) — meant to make inspections more consistent, but four months later questions remain about its day-to-day operations. Read More
A bill that functions as a followup to the 21st Century Cures Act of 2016 has been introduced that includes many provisions that would affect the FDA and drugmakers. Read More
The COVID-19 vaccine partnership was the result of a four-year collaboration originally meant to develop vaccines for several other diseases. Read More
Majority Leader Steny Hoyer (D-Md.) said House Democrats plan to vote Thursday — or at the latest Friday — on the nearly $2 trillion Build Back Better Act, which contains compromise provisions meant to lower the price of prescription drugs. Read More